Divergent effects of rofecoxib on endothelial function and inflammation in acute coronary syndromes

International Journal of Cardiology

Volumn 112, Issue 3, 2006, Pages 359-366

  Lekakis, John P ^a   Vamvakou, Georgia ^a   Andreadou, Ioanna ^a   Ganiatsos, George ^a   Karatzis, Emmanouil ^a   Protogerou, Athanassios ^a   Papaioannou, Theodore ^a   Ikonomidis, Ignatios ^a   Papamichael, Christos ^a   Mavrikakis, Myron E ^a  

^a ALEXANDRA HOSPITAL   (Greece)

Author keywords

Coronary disease; Endothelium; Inflammation; Oxidative damage

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENOXAPARIN; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW MOLECULAR WEIGHT HEPARIN; MALONALDEHYDE; NITRIC ACID DERIVATIVE; ROFECOXIB;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTERY DILATATION; ARTICLE; BRACHIAL ARTERY; CARDIOVASCULAR SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIUM; ENZYME INHIBITION; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; INFLAMMATION; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; ADULT; AGED; ANGINA, UNSTABLE; C-REACTIVE PROTEIN; CYCLOOXYGENASE 2 INHIBITORS; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; HUMANS; INTERLEUKIN-6; LACTONES; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MIDDLE AGED; MYOCARDIAL INFARCTION; OXIDATIVE STRESS; PROSPECTIVE STUDIES; RISK FACTORS; SULFONES;

EID: 33748758172     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2005.10.011     Document Type: Article

References (31)

1. Mukherjee D., Nissen S.E., and Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286 (2001) 954-959
2. Cheng Y., Austin S.C., Rocca B., et al. Role of prostacyclin in the cardiovascular response tï thromboxane A2. Science 296 (2002) 539-541
3. Drazen J.M. COX-2 inhibitors-a lesson in unexpected problems. N Engl J Med 352 (2005) 1131-1132
4. Chenevard R., Hurlimann D., Bechir M., et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 107 (2003) 405-409
5. Bogaty P., Brophy J., Noel M., et al. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-Reactive protein. A randomized placebo-controlled study. Circulation 110 (2004) 934-939
6. Widlansky M., Price D., Gokce N., et al. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 42 (2003) 310-315
7. Title L.M., Giddens K., McInerney M.M., McQueen M.J., and Nassar B.A. Effect of cyclooxygenase-2 inhibitor with rofecoxib on endothelial function and inflammatory markers in patients with coronary artery disease. J Am Coll Cardiol 42 (2003) 1754-1756
8. Monakier D., Mates M., Klutstein M.W., et al. Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes. Chest 125 (2004) 1610-1615
9. Bulut D., Liaghat S., Hanefeld C., et al. Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension. J Hypertens 21 (2003) 1663-1667
10. Antman E.M., Cohen M., Bernink P.J., et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision-making. JAMA 284 7 (2000) 835-842
11. Corretti M.C., Anderson T.J., Benjamin E.J., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. J Am Coll Cardiol 39 (2002) 257-265
12. Andreadou I., Tasouli A., Iliodromitis E., et al. Reduction of myocardial infarct size in rabbits by a novel indole derivative with antioxidant and free radical scavenging properties. Eur J Pharmacol 453 (2002) 271-277
13. Bogaty P., Dagenais G.R., Poirier P., et al. Effect of atorvastatin on exercise-induced myocardial ischemia in patients with stable angina pectoris. Am J Cardiol 92 (2003) 1192-1195
14. Cavalca V., Cighetti G., Bamonti F., et al. Oxidative stress and homocysteine in coronary artery disease. Clin Chem 47 (2001) 887-892
15. Holvoet P., Vanhaecke J., Janssens S., Van de Werf F., and Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary symptoms and stable coronary artery disease. Circulation 98 (1998) 1487-1494
16. Karatzis E., Lekakis J.P., Papamichael C., et al. Rapid effect of pravastatin on endothelial function and lipid peroxidation in unstable angina. Int J Cardiol 11 (2005) 65-70
17. O'Banion M.K. Cyclooxygenase-2: molecular biology, pharmacology and neurobiology. Crit Rev Neurobiol 13 (1999) 45-82
18. Heitzer T., Schlinzig T., Krohn K., Meinertz T., and Munzel T. Endothelial dysfunction, oxidative stress and risk of cardiovascular events in patients with coronary artery disease. Circulation 104 (2001) 2673-2678
19. Rosenson R., and Koenig W. Utility of Inflammatory markers in the management of coronary artery disease. Am J Cardiol 92 (2003) 10i-18i
20. Ferreiros E.R., Boissonnet C.P., Pizarro R., et al. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation 100 (1999) 1958-1963
21. Lindahl B., Toss H., Siegbahn A., Venge P., and Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 343 (2000) 1139-1147
22. Rader D.J. Inflammatory markers of coronary risk. N Engl J Med 343 (2000) 1179-1182
23. Biasucci L.M., Liuzzo G., Fantuzzi G., et al. Increasing levels of interleukin (IL)-1 Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 99 (1999) 2079-2084
24. Altman R., Luciardi H.L., Muntaner J., et al. Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation. The NSAID in unstable angina treatment-2 (NUT-2) Pilot Study. Circulation 106 (2002) 191-195
25. Schönbeck U., Sukhova K.G., Graber P., et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 155 (1999) 1281-1291
26. Burleigh M.E., Babaev V.R., Oates J.A., et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 105 (2002) 1816-1823
27. Verma S., Raj S., Shewchuk L., Mather K.J., and Anderson T.J. Cycloxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers. Circulation 104 (2001) 2879-2882
28. Anderson T. Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. Heart Fail Rev 8 (2003) 71-86
29. Yu H., Wayne, Sheu W.H., Lai C., Lee W., and Chen Y. Endothelial dysfunction in type 2 diabetes mellitus subjects with peripheral artery disease. Int J Cardiol 78 (2001) 19-25
30. Hermann M., Camici G., Fratton A., et al. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 108 (2003) 2308-2311
31. Chew D.P., Bhatt D.L., Robbins M.A., et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 88 6 (2001 (Sep. 15)) 672-674